Last reviewed · How we verify
cP12
At a glance
| Generic name | cP12 |
|---|---|
| Sponsor | Neomatrix Therapeutics, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Safety, Tolerability and Pharmacokinetic Study of cP12 in Adults With Up To 10% Total Body Surface Area Burns (PHASE2)
- Association Study Between CYP1A2 Gene Polymorphisms and Metabolism of Theophylline (NA)
- Personalized Nutrition Caffeine Intake in Healthy Adults. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cP12 CI brief — competitive landscape report
- cP12 updates RSS · CI watch RSS
- Neomatrix Therapeutics, Inc. portfolio CI